CITIC-Prudential CSI 800 Pharmaceuticals and Biotechnology Index Fund(LOF)-A

Fosun Pharma Subsidiary's Levofloxacin Injection Approved

Fosun Pharma's Hengrui Medicine Receives Approval for Phase I Clinical Trial of HLX48 for Solid Tumors

2025 Top 10 Domestic Innovative Drug Companies Revenue Surpasses 100 Billion, BeiGene Leads Turnaround

HKEX Discloses: JPMorgan Increases Short Position in Wuxi AppTec H-Share to 3.34% on May 14

BeiGene 2026 Q1 Earnings Soar: Net Profit Surges 178x, Revenue Breaks 10 Billion RMB Barrier

Schroders PLC Increased Holdings in Hengrui Medicine by 663,000 Shares on May 12 at Cost of Approx. 45.55 Million HKD

BlackRock Increases Stake in Wuxi AppTec H-Shares to 6.32%

BeiGene's Sorotorac Gets FDA Accelerated Approval, Deepening BCL-2 Layout to Mitigate Single-Product Risk

Bristol Myers Squibb and Hengrui Medicine Reach Billions-Deal to Co-Develop Drugs and Conduct Early Clinical Trials in China

Orient Securities: WuXi AppTec 2026 Q1 Net Profit 4.65B, Maintains Buy Rating with Target Price 140.16 Yuan

Hengrui Medicine and BMS Reach $15.2 Billion Super BD Deal

Fosun Pharma: Expected to submit NDA by year-end

Hengrui Medicine's Subsidiary Receives Approval for SHR-3079 Injection Clinical Trials

Hengrui Medicine Receives Approval for Three Drugs' Clinical Trials

BeiGene's Brukinsa Approved by FDA

Fosun Pharmaceutical's Subsidiary Receives Acceptance for Peach Red Four Ingredients Granule Drug Registration Application

Fosun Pharma Industry Acquires Exclusive Option from AriBio

Jiangsu Hengrui Medicine Signs $950 Million Global R&D Agreement with Bristol-Myers Squibb

399933

165519

159647

161726

<p>The Penghua CSI Chinese Medicine ETF rose by more than 1.8%, influenced by the opinions on the pricing mechanism for pharmaceuticals released by the General Office of the State Council. The opinion aims to regulate the prices of raw and auxiliary materials for medicines and promote the development of high-quality and high-priced Chinese medicinal materials. Institutional analysis suggests that Chinese medicine companies have low valuations and high dividend rates, and will benefit from policy support and market recovery in the future. The CSI Chinese Medicine Index rose by 2.04%, with many Chinese medicine stocks performing strongly. Overall, the state supports the development of traditional Chinese medicine, and the industry is expected to achieve high-quality growth</p>

腾讯新闻 - 财经

800 Health Care

Penghua CSI Chinese Medicine ETF

China Merchants CNI BIOMEDICINE Index Fund-A

CONBA

Zhongheng Group

BUCHANG PHARMA

ZHONGSHENGYAOYE

YABAO PHARM.CORP

Yunnan Baiyao

ZZPZH

DEEJ

CR Sanjiu

JI LIN AO DONG

GYBYS

BAIYUNSHAN PH

YILING PHARMACEUTICAL

DRTG

TONG REN TANG

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

603858

<p>Penghua CSI Chinese Medicine ETF net subscribed 36.5 million units, and the State Administration for Market Regulation approved three national standards in the field of acupuncture, which will be implemented starting October 1. Zhongtai Securities analysis pointed out that the reform of medical insurance payment promotes the construction of the clinical value evaluation system for traditional Chinese medicine, and traditional Chinese medicine products with RCT evidence chains are more likely to gain access to medical insurance. The performance of the CSI Traditional Chinese Medicine Index constituent stocks was poor, with BUCHANG PHARMA leading the decline at 3.17%. Penghua CSI Chinese Medicine ETF closely tracks the CSI Traditional Chinese Medicine Index, reflecting the overall performance of listed companies in the traditional Chinese medicine concept</p>

Capital allocation, Penghua CSI Chinese Medicine ETF net subscription of 36.5 million units, policies continuously improving to support the development of traditional Chinese medicine

CITIC-Prudential CSI 800 Pharmaceuticals and Biotechnology Index Fund(LOF)-A(165519.SZ)

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

Capital allocation, Penghua CSI Chinese Medicine ETF net subscription of 36.5 million units, policies continuously improving to support the development of traditional Chinese medicine